Cargando…
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
BACKGROUND: Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The present study evaluated the safety and efficacy of sirukumab, as monotherapy in...
Autores principales: | Takeuchi, Tsutomu, Yamanaka, Hisashi, Harigai, Masayoshi, Tamamura, Ryo, Kato, Yuichi, Ukyo, Yoshifumi, Nakano, Toshikazu, Hsu, Benjamin, Tanaka, Yoshiya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842593/ https://www.ncbi.nlm.nih.gov/pubmed/29514712 http://dx.doi.org/10.1186/s13075-018-1536-9 |
Ejemplares similares
-
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)
por: Aletaha, Daniel, et al.
Publicado: (2021) -
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011) -
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016) -
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
por: Takeuchi, Tsutomu, et al.
Publicado: (2017) -
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)